Get the Stockscreener App
4.00
3.90%
0.15
Medicus Pharma Ltd stock is traded at $4.00, with a volume of 13,507.
It is up +3.90% in the last 24 hours and up +35.59% over the past month.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
See More
Previous Close:
$3.85
Open:
$4.1
24h Volume:
13,507
Relative Volume:
0.26
Market Cap:
$48.43M
Revenue:
-
Net Income/Loss:
$-11.73M
P/E Ratio:
-2.8931
EPS:
-1.3826
Net Cash Flow:
$-10.37M
1W Performance:
+19.40%
1M Performance:
+35.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.8501
$4.18
1-Week Range:
$3.36
$4.18
52-Week Range:
$1.80
$4.99
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
4.00 | 48.43M | 0 | -11.73M | -10.37M | -1.3826 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma (NASDAQ:MDCX) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Medicus Pharma initiated with a Buy at D. Boral Capital - TipRanks
Medicus Pharma Ltd. - FinancialContent
This Millrose Properties Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
FY2025 EPS Estimate for Medicus Pharma Lifted by Analyst - Defense World
Brokers Set Expectations for Medicus Pharma Q1 Earnings - The AM Reporter
Research Analysts Set Expectations for Medicus Pharma Q1 Earnings - Defense World
Medicus Pharma secures $15 million funding option - MSN
Will Medicus' D-MNA Prove To Be A Non-Invasive, Effective Alternative To Mohs Surgery For BCC? - RTTNews
Medicus Pharma Ltd. SEC 10-K Report - TradingView
Medicus Pharma Ltd. (MDCX) reports earnings - Quartz
Healthcare Disruptors: AI, Telehealth and Cost Savings - Value The Markets
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out - WRAL.com
ValueTheMarkets Insights: Healthcare Climbs as Tech Stumbles in 2025 Shift - WRAL.com
Healthcare Climbs as Tech Stumbles in 2025 Shift - Value the Markets
While Big Pharma Stalls, One Small-Cap Breaks Out - Value the Markets
Medicus Pharma cancels shareholder meeting notice By Investing.com - Investing.com Australia
Medicus Pharma cancels shareholder meeting notice - Investing.com
Pinpointing Hidden Stock Winners in a Volatile Market - Value the Markets
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%! - Value The Markets
Medicus Pharma announces annual meeting date - Investing.com
Medicus Pharma announces annual meeting date By Investing.com - Investing.com Australia
Advancing Oncology: Innovations in Treatment and Detection - Value The Markets
See Why Some Investors Are Watching This Biotech Company - Value The Markets
Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity - Value The Markets
The Biotech Stocks Tackling the World’s Most Common Cancer - Value The Markets
Medicus Pharma - The Pharma Letter
Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials - TipRanks
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering - Newsfile
Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment - Dermatology Times
Medicus Pharma CEO discusses latest skin cancer trial resultsICYMI - Proactive Investors
Encouraging Interim Data for Innovative Skin Cancer Patch - Value The Markets
Small cap wrap: G Mining Ventures, Wedgemount Resources, Medicus Pharma... - Proactive Investors UK
Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating - TipRanks
Medicus Pharma unveils pricing of financing to advance skin cancer treatment - Proactive Investors Australia
Can This $4.2M Funding Advance Medicus Pharma's Novel Skin Cancer Patch to Market? - StockTitan
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering - Newsfile
Clinical Study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE - Proactive Investors USA
Small cap wrap: Petro-Victory Energy, NexTech3D.ai, Medicus Pharma, Nano One Technology... - Proactive Investors UK
Market movers: Tesla, Marvell, Petro-Victory, Medicus Pharma... - Proactive Investors USA
Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial - Value the Markets
High Demand, Few Options: The Skin Cancer Treatment Gap - Value The Markets
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results - Proactive Investors Australia
Medicus Pharma Announces Positively Trending Interim Analysis For SKNJCT-003 Phase 2 Clinical Study - Marketscreener.com
Medicus Pharma announces positively trending interim analysis for SKNJCT-003 - TipRanks
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - GlobeNewswire
Can This New Skin Cancer Treatment Replace Surgery? Phase 2 Trial Reveals Promising Results - StockTitan
A Breakthrough in Non-Invasive Skin Cancer Treatment - Value The Markets
Why Reddit Stock Lost 19% in February - The Globe and Mail
Sea (SE) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):